Show simple item record

dc.contributor.authorBerney, DM
dc.contributor.authorGopalan, A
dc.contributor.authorKudahetti, S
dc.contributor.authorFisher, G
dc.contributor.authorAmbroisine, L
dc.contributor.authorFoster, CS
dc.contributor.authorReuter, V
dc.contributor.authorEastham, J
dc.contributor.authorMoller, H
dc.contributor.authorKattan, MW
dc.contributor.authorGerald, W
dc.contributor.authorCooper, C
dc.contributor.authorScardino, P
dc.contributor.authorCuzick, J
dc.contributor.authorGrp, T-AP
dc.date.accessioned2018-08-30T08:13:30Z
dc.date.issued2009-03-17
dc.identifier6
dc.identifier.citationBRITISH JOURNAL OF CANCER, 2009, 100 pp. 888 - 893
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2412
dc.identifier.doi10.1038/sj.bjc.6604951
dc.description.abstractTreatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67 provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method, Delta chi(2) (1 d.f.) = 24.6 (P<0.0001), overall survival chi(2) = 20.5 (P<0.0001), and for the quantitative method, Delta chi(2) (1 d.f.) = 15.1 (P < 0.0001), overall survival chi(2) = 10.85 (P = 0.001). Ki-67 is a powerful biomarker in localised prostate cancer and adds to a model predicting the need for radical or conservative therapy. As it is already in widespread use in routine pathology, it is confirmed as the most promising biomarker to be applied into routine practice.
dc.format.extent888 - 893
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleKi-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/sj.bjc.6604951
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2009-03-17
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBRITISH JOURNAL OF CANCER
pubs.notesaffiliation: Berney, DM (Reprint Author), Barts & London Queen Marys Sch Med & Dent, Orchid Tissue Lab, Ctr Mol Oncol, London, England. Berney, D. M.; Kudahetti, S., Barts & London Queen Marys Sch Med & Dent, Orchid Tissue Lab, Ctr Mol Oncol, London, England. Gopalan, A.; Reuter, V.; Gerald, W., Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. Fisher, G.; Cuzick, J., Univ London, Canc Res UK Ctr Epidemiol Math & Stat, Wolfson Inst Prevent Med, St Bartholomews Med Sch, London, England. Foster, C. S., Liverpool Univ Hosp, Dept Cellular Pathol & Mol Genet, Liverpool, Merseyside, England. Eastham, J.; Scardino, P., Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA. Moller, H., Kings Coll London, Thames Canc Registry, London WC2R 2LS, England. Kattan, M. W., Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA. Cooper, C., Royal Marsden Hosp, Inst Canc, Sutton, Surrey, England. keywords: prostate cancer; Ki-67; watchful waiting; active surveillance; biomarker keywords-plus: MONOCLONAL-ANTIBODY KI-67; RADICAL PROSTATECTOMY; CELL-PROLIFERATION; DISTANT METASTASIS; NUCLEAR ANTIGEN; RADIOTHERAPY; EXPRESSION; CARCINOMA; MEN; P53 research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] orcid-numbers: Moller, Henrik/0000-0001-8200-5929 Berney, Daniel/0000-0001-5474-8696 funding-acknowledgement: Cancer Research UK; National Institute of Health (SPORE); Koch Foundation; NCRI; Grand Charity of Freemasons; Orchid Appeal; Medical Research Council [G0501019] funding-text: This study was supported by Cancer Research UK, The National Institute of Health (SPORE), The Koch Foundation, The NCRI and the Grand Charity of Freemasons and The Orchid Appeal. number-of-cited-references: 26 times-cited: 81 usage-count-last-180-days: 0 usage-count-since-2013: 5 journal-iso: Br. J. Cancer doc-delivery-number: 420RH unique-id: ISI:000264306400005 oa: gold_or_bronze da: 2018-08-29
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cell Transformation
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cell Transformation
pubs.volume100
pubs.embargo.termsNot known
icr.researchteamCell Transformationen_US
dc.contributor.icrauthorCooper, Colinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0